

Iconovo release briefing document for ICOp^{re}[®] development

Today, Iconovo released a briefing document on its homepage covering the market opportunity, patent situation, ICOp^{re}[®] product features and partnering strategy. The objective is to be transparent to customers and investors regarding Iconovo's perception of this product opportunity.

To find the briefing document, please follow the link: www.iconovo.se/products/icopre.

"ICOp^{re} is the largest investment in the history of Iconovo and we want to share how we view this opportunity with investors and potential customers. We will keep our stakeholders informed about the progress in the development of ICOp^{re} as we move forward. Iconovo is already investigating potential partnering interest with generic customers for this opportunity" says Johan Wäborg, CEO of Iconovo.

Contacts

Johan Wäborg, CEO

+46 707 78 51 71

johan.waborg@iconovo.se

About Iconovo

Iconovo was founded in 2013 by people with long experience in inhalation development. The company develops inhalers and associated drug preparations that are used to treat asthma and COPD. However, Iconovo also has the competence to develop products for new types of inhaled drugs such as vaccines.

By working with Iconovo, pharmaceutical companies and generic companies can access a complete pharmaceutical product, thereby eliminating the complex and costly early stages of the development phase. Iconovo licenses its patented products to customers and offers a faster way to the inhalation market with lower risk and at a lower cost.

More information about the company can be found at www.iconovo.se.

Iconovo is based in Lund and its share (ticker ICO) is listed on Nasdaq First North Growth Market, Stockholm since April 6, 2018. The Company's Certified Adviser is Erik Penser Bank AB, Box 7405, SE-103 91 Stockholm, phone +46 8 463 80 00, email: certifiedadviser@penser.se.

Attachments

[Iconovo release briefing document for ICOp^{re}[®] development](#)

[ICOp^{re} Briefing Document](#)